INTERNATIONAL JOURNAL FOR INNOVATIVE RESEARCH IN MULTIDISCIPLINARY FIELD
ISSN(O): 2455-0620 [Impact Factor: 7.581]
Monthly, Peer-Reviewed, Refereed, Indexed Journal with IC Value : 86.87
Volume - 9, Issue - 6, June - 2023 Publication Date: 30/06/2023

DOIs:10.2015/IJIRMF/202306023 --:-- Research Paper / Article / Review

A Review on Transfusion Medicine- Erythroblastosis Fetalis

[1]Neema Manase, [2]Paramita Dey
[1]Student, Department of Paramedical and Allied Health Sciences, Galgotias University, UP, India
[2]Assistant Professor, Department of Paramedical and Allied Health Sciences, Galgotias University, UP, India
Email – [1]neemamanase2016@gmail.com, [2]paramita.dey@galgotiasuniversity.edu.in

Abstract: *Erythroblastosis fetalis commonly referred to as alloimmune HDFN or HDFN, is a disorder brought on by the maternal immunoglobulin of IgG Antibodies (Ab) destroying the neonatal red blood cells. The development of newborn hyperbilirubinemia that can result in kernicterus and foetal anaemia due to maternal alloimmunization against red blood cell antigens. Despite antenatal and postnatal Anti-D immunoglobulin therapy, erythroblastosis fetalis instances are primarily caused by Anti-D. This results in intrauterine foetal death from heart failure, ascites, and effusion, a disease known as hydrops foetal. This review, show the highlights strategies of the clinical relevance of Red Cells alloantibodies in association with HDN (Erythroblastosis fetal occurrence) on its management, screening, prevention, and treatment of RBC alloimmunization to women bearing potential children.*

Key Words: *Erythroblastosis fetalis (HDN), Red cells alloantibodies, Anti-D prophylaxis, Alloimmunization in pregnancy, phototherapy, amniocentesis, Direct and Indirect Coombs Tests.*

1. INTRODUCTION:

Hemolytic anaemia in the foetus (or newborn, as blood disease neonatorum) is referred to as erythroblastosis fetalis. This anaemia is brought on by the placenta's transfer of maternal antibodies to the foetus' red blood cells. Rho(D) antigens, which are normally incompatible in maternal and foetal blood teams, are the usual cause of the illness.[1] When a woman with a Rh-negative blood type is fertilised by a person with a Rh-positive blood type and has a foetus with Rh-positive blood, which causes hemolysis, erythroblastosis fetalis can ensue. The Kell, Duffy, Kidd, MNSs, Lutheran, Diego, Xg, P, Ee, and Cc matter systems are further fetomaternal incompatibilities that may result in anaemia [2].Erythroblastosis in infants is a blood illness that primarily affects blood destruction and regeneration. The risk of severe anaemia is essentially the only danger to the fetus's life and wellbeing. Due to the availability of transfusions, the issue of anaemia becomes insignificant once the baby is born. if the foetus lacks symptoms and is already extremely anaemic.

A hemolytic malady of the Fetus and newborn (HDFN) :

A condition known as hemolytic disease of the foetus and newborn (HDFN), also known as alloimmune HDFN or anaemia, is brought on by the maternal IgG (IgG) antibodies destroying the infant's or foetus' red blood cells (RBCs). Isoimmunization refers to the production of maternal antibodies in response to a foetal chemical. [3]These antibodies are produced when foetal erythrocytes that are specific for particular cell antigens that aren't evident in the mother's blood cross the placenta. This protein reaction is also capable of killing foetal red blood cells, which causes lysis, the release of animal pigment, and anaemia. Numerous variables, including as the amount and quality of protein produced by the foetus, affect the severity of the illness.

HDFN involves many blood type systems, including ABO, Rhesus (Rh), Kell, Duffy, Kidd, MNS, and Diego. Lutheran, Xg, and P. [4]The Rhesus Factor and ABO blood type are not particularly similar. ABO incompatibility typically affects a group A or B infant born to a mother with an excessive blood type, however it is less severe than Rh(D) incompatibility in terms of the newborn's lysis illness. Infant jaundice, which is occasionally successfully treated with actinotherapy, develops in affected infants who are normally asymptomatic at birth with absent or mild anaemia. B-lymphocyte clones that recognise the cell material are created after maternal exposure to RhD-positive blood. IgM isotype production is the initial maternal immunological response. It's essential to take note when 250 ml of Rh-positive cells have been exposed. In subsequent pregnancies, the maternal Ig response develops later. Repeated exposure to a level as low as zero is followed by a subsequent immunological response.Rh-positive cells in 0.3 millilitres.

Maternal anti-D (IgG) antibodies bind to Rh antigens on foetal RBCs after crossing the placenta. By lysing antibody-coated RBCs with scavenger cell lysosomal enzymes, corpuscles are destroyed. Through reticulocytosis, the foetus responds to the subsequent anaemia and tissue drive, and an increase in point artery wet-nurse signals severe foetal anaemia. When cell death surpasses cell creation, anaemia develops.[5]
Erythroblastosis fetalis is often caused because of incompatibility of either of 2 major blood varieties

These embody:
Rh incompatibility and Abo incompatibility
Only a small percentage of foetuses show symptoms of illness incompatibility sickness, despite the fact that a small percentage of foetuses have their mother's antibodies in circulation.[6] Rh incompatibility, illness sickness of the Newborn-disease sickness of the Newborn, and Abo incompatibility are less damaging to the foetus.
The Rh blood grouping method is based on whether or not the Rh is present on the surface of the erythrocyte.

Rh incompatibility happens when:

- If the father is Rh+, a Rh mother will conceive an associate degree Rh+ craniate.



- Due to outflow, the foetal erythrocyte may enter the mother's bloodstream upon birth.As a result, the mother's body produces antibodies against the foetus' RBCs that contain the Rh factor [7].

Since maternal antibodies are only produced during delivery, the firstborn is usually spared.



- Since maternal antibodies are only produced during delivery, the firstborn is usually spared.
- In the event that the woman conceives another Rh+ foetus, her antibodies will cross the placenta and target the foetal RBCs, resulting in severe anaemia.
- In response to anaemia, the foetal bone marrow releases cathartic immature RBCs known as erythroblasts into the foetal peripheral circulation, causing anaemia.

ABO incompatibility:
Maternal antibodies against her baby's blood cells may result from a different form of blood group disagreement. When the mother's A, B, or O ancestry is incompatible with the babies, this occurs.[8] This disorder frequently poses less of a concern to the unborn child than Rh incompatibility. However, newborns will have uncommon antigens in their bodies that could put them at risk for anaemia.
These antigens comprise:

- Kell
- Duffy
- Kidd
- Lutheran

- Diego & MNSs
- Xg & Cc

2. SYMPTOMS AND SIGNS OF ERYTHROBLASTOSIS FETALIS:

Even when very little volumes of Rh-positive and blood groups meet, issues will still occur. Although it is uncommon for blood to mix between the mother and foetus during pregnancy,[9] it could occur for the following reasons:

- The placenta detaching from the wall of the womb wall throughout the delivery
- Bleeding throughout gestation
- Manual rotation of a breech baby
- Abortion
- An eccyesis
- A miscarriage
- A fall, harm, or invasive prenatal testing
- Prenatal tests, like Associate in Nursing prenatal diagnosis or villus sampling (CVS)

Rh sensitization, an immunologic reaction, could happen if the blood group mixes with Rh-positive blood. This implies that a blood type holder can produce antibodies to protect themselves from any future contact with Rh-positive blood. After coming into contact with Rh-positive blood through a needle or a transfusion, the body may also begin to produce antibodies.

After becoming supersensitive, the body's defences will be able to identify and attack any future Rh-positive cells as foreign.

The body of a woman with a sensitised blood group can attack and destroy incursive cells if Rh-positive blood from a foetus enters her circulation.

The clinical manifestations of erythroblastosis fetalis (anaemia) are caused by maternal antibodies that attack foetal RBCs and cause their destruction. they will differ from

The major symptoms of anemia area unit concisely mentioned below:

- Jaundice

This occurs because bilirubin, a byproduct of hemoprotein breakdown from RBCs, accumulates in the skin and consequently the whites of the eyes. This gives those buildings a yellowish look.

Hemolytic Anemia:

This happens because of the destruction of RBCs.[10] Untreated anemia will cause cardiopathy enlarged liver and/or spleen, generalized swelling, and metabolic process distress.



- **Kernicterus**

This happens because of the deposition of animal pigment within the brain and funiculus. this may cause neuron degeneration, hearing impairment, subnormality, and even death.[11]



Hypoxic-ischemic injury (HII):

- **Hydrops Fetalis:**
  This is the most severe form of the disease among neonates, and it is distinguished by severe edoema (an abnormal buildup of liquid body fluid in unexpected areas, such as the belly, heart, and lungs). As a result of the extra fluid causing increased pressure on the heart and lowering its ability to pump, this may result in signs of coronary failure. In addition, a buildup of fluid in the lungs impairs normal respiratory function, which limits how much room the lungs can expand.[12]



- **Erythroblastosis fetalis destroys red blood cells:**

Hemolysis, the rapid destruction of red blood cells, may occur in an extremely developing foetus. The foetus won't get enough oxygen as a result, which could lead to anaemia, other illnesses, or even death. The foetus can rapidly commit to developing new red blood cells as hemolysis progresses.[13] However, the new red blood cells produced by these cells are often immature and unable to function effectively.The liver and spleen create red blood cells, therefore this excess usually results in the growth of these organs. This disorder is known as a neonatal hemolytic disease when it affects a baby.Bilirubin builds up when the immature red blood cells continue to degrade, which may be a by-product of this process. Jaundice, in which the child's skin and eye whites turn yellow, can be brought on by the body of the infant having too much bilirubin.

Symptoms of anemia throughout gestation could show up throughout routine testing:

- Yellow amniotic fluid, umbilical cord, skin, or eyes, either at birth or at intervals of 24 to 36 hours (about 1.5 days) after delivery.
- Newborns with this condition could show visible symptoms yet some show au fait scans, such as pale skin.
- Yellow amniotic fluid from an associated amniocentesis operation that examines the amniotic fluid, with traces of hematoidin.
- An enlarged spleen, heart, or liver
- A buildup of fluid in the belly, lungs, or scalp that can be seen during a pregnancy ultrasound scan.

3. DIAGNOSTIC:

Several diagnoses Unconjugated haematoidin elevation has a wide range of causes. Physiological jaundice is the most common cause. Around day two or three, physiological jaundice appears with a serum haematoidin level of

only twelve mg/dL, primarily unconjugated. [14] Due to a limited ability to conjugate hemosidein, it predictably vanishes by the end of the first week in one hour of term and eighty percent of preterm children. Maternal polygenic disease,[15] blood disease, hemorrhagic cyst, premature birth, Asian or male gender, Down syndrome, delayed movement or higher epithelial duct obstruction, hypothyroidism, and a family member who has physiological jaundice are risk factors. When it occurs within the first twenty-four hours after giving birth, jaundice is not physiological and has to be examined. The most frequent cause of pathologic unconjugated hyperbilirubinemia is early-onset nursing jaundice. Breastfeeding will increase physiological jaundice during the first week of life due to caloric restriction, increasing enterohepatic circulation and reducing the biological process of haematoidin via the stomach. Successful nursing every two to three hours while monitoring poop and stool production to see whether the infant is eating enough significantly reduces the risk of hyperbilirubinemia. [16] Breast milk's capacity to block two,3 UDP glucuronyl transferase,[17] the enzyme responsible for conjugating haematoidin, is secondary to breast milk's propensity to cause jaundice, which only occurs once during the first week of life. Unconjugated hyperbilirubinemia has genetic causes, such as Gilbert syndrome, which manifests as jaundice later in life after experiencing minor illnesses, fasting, or physical strain. A deficiency in UDP glucuronosyltransferase causes Gilbert syndrome. Because of a lack of or a decline in UDP glucuronosyltransferase, Crigler-Najjar occurs.

In addition to Rh/ABO incompatibility, other factors that contribute to an increase in haematoidin production include structural defects (spherocytosis and elliptocytosis), catalyst defects (glucose-6-phosphate deficiency and pyruvate enzyme deficiency), birth trauma (cephalohematoma and excessive bruising), and blood disorders. Complete blood count, erythrocyte count, blood smear, serum haptoglobin, direct and indirect Coombs tests, hemoprotein electrophoresis, red cell catalyst assay, and spherocytosis test are all included in the work-up for indirect hyperbilirubinemia.

Blood Tests Comprises

- A Direct Coombs test, which counts the number of maternal antibodies linked to the baby's RBCs, is performed on the foetal blood sample. If the foetus exhibits signs of anaemia and jaundice, the test is considered successful. foetal blood counts and serum haematoidin levels tests to check for anaemia and jaundice, respectively. In another instance, even when there is no Rh incompatibility, the newborn may nonetheless experience jaundice after birth. Under these conditions, Abo incompatibility is blamed for the symptoms. However, compared to just Rh incompatibility, the symptoms are much milder.
- If the mother is discovered to be Rh- at the prenatal visit and the father is Rh+, an indirect Coombs test is performed on her blood. It counts the quantity of antibodies present in the mother's blood. If the Rh mother is initially negative for antibodies, she will be tested again at eighteen to twenty weeks of pregnancy and again at twenty-six to twenty-seven weeks. At any of those times, therapy is started if anti-Rh antibodies are found.



Doppler Ultrasound:

Doppler ultrasonography with foetal middle arteria cerebri blood flow monitoring is ordered as a non-invasive test.[19] Erythroblastosis fetalis should be detected if the fetus's blood supply is compromised.



Amniocentesis:

The amniotic fluid that surrounds the developing foetus inside the uterus is pattern using this technique. In order to take a fluid pattern, a needle is placed into the amnion (the sac that contains amniotic fluid). This is looked at within the lab to assess the risk of anaemia for the infant. Additionally, a bilirubin assessment of the amniotic fluid can be used to predict the severity of the condition. If the tiers are elevated, Rh blood may be infused intrauterinally until an impromptu transport can be induced.[9]



4. PROGNOSIS:

The diagnosis of this condition has advanced significantly over the past few years because to technological advancements and noninvasive tests that, when performed during pregnancy, will trigger early awareness and treatment. Foetal survival rates for non-hydropic and hydropic foetuses were determined to be 94% and 74%, respectively, based on data from various studies that addressed situations managed with the help of foetal transfusion. In a large database of over 300,000 births, neonates at risk for HDFN due to alloantibodies other than anti-Rh(D) were substantially more likely to develop icterus (25% vs. 10%) and require phototherapy (17% vs. 5%) than those who were no longer at risk. The first step in diagnosing erythroblastosis fetalis is to decide whether or not the reason is Rh incompatibility.
A physician can become aware of incompatibility with the use of an antibody screening and take a look at it withinside the first trimester. They can also additionally repeat the take a look at 28 weeks of gestation and might additionally take a look at the Rh component of the male partner.

Fetal checking out can also additionally include:

- An ultrasound
- Amniocentesis, wherein the medical examiner extracts and checks amniotic fluid
- Fetal center cerebral artery blood glide measurement, to check blood motion withinside the mind
- Fetal umbilical twine blood checking out, to study the content material of blood from the fetus

In the newborn, a medical doctor can also additionally perform checks to evaluate:

- blood group and Rh component
- RBC's count
- Antibodies and bilirubin ranges

5. COMPLICATIONS:

A high-output heart failure or myocardial ischemia can be brought on by anaemia. The myocardium will become dysfunctional as the cardiac device tries unsuccessfully to keep pace with the oxygen transport demands, leading to effusions, edoema, and ascites because hydrostatic strain will grow. The term "hydrops fetalis" refers to a combination of fluid buildup in at least extravascular compartments (pleural effusion, ascites, pericardial effusion, or subcutaneous edoema). Unconjugated bilirubin has the ability to cross the blood-brain barrier (BBB) and cause kernicterus since it is lipid-soluble. Oblique bilirubin levels more than 20 or increasing levels increase the risk of kernicterus, regardless of phototherapy. Lethargy and poor eating are symptoms of kernelicterus, which can be identified by a toxic appearance, respiratory distress, and weakened deep tendon reflexes. Additionally, infection, suffocation, hypoglycemia, and cerebral haemorrhage can all look like kernicterus. Acidosis and sepsis, which will enhance BBB permeability, will raise the risk of kernicterus. Hypoalbuminemia also increases the risk since it lowers the body's ability to transport unconjugated bilirubin to the liver. And last, the use of tablets increases the risk.

6. TREATMENT:

A foetal blood transfusion and birth of the foetus between 32 and 37 weeks of gestation may also be included in the course of treatment.
Treatment alternatives for newborns with the circumstance comprise:

- Blood transfusion
- IV immunoglobulin (IVIG)
- Managing respiration problems
- Intravenous (IV) fluids

The goal of the IVIG antibody treatment is to reduce levels of circulating bilirubin and the destruction of red blood cells. Occasionally, a different transfusion is required.[20] This type of transfusion involves mixing small amounts of one blood type with another. The goal is to increase the quantity and presence of red blood cells while lowering bilirubin levels.
Before the baby is born, the following treatment strategies may be adopted:

- Blood Transfusion
  The infant may also need blood transfusions before they are even started in order to treat anaemia.[21] The umbilical cord is used to administer intrauterine blood transfusion.



Pre-term Delivery: In good circumstances, the baby wants to be born before its full-term period. So, while the baby's lungs and heart are developed enough for delivery, the doctor might also advise turning the baby during the pre-partum period (usually between 32 and 35 weeks). The newborn may also desire to undergo extra blood transfusions after birth. Intravenously injected fluids can be used to raise low blood pressure. To treat respiratory insufficiency, mechanical breathing assistance may also be necessary. The short-listed approaches below are some unusual ones that can be used.

Exchange Transfusion:

The infant's blood is swapped with the donor's blood in this unusual form of transfusion. In this approach, excess bilirubin and the anti-Rh antibodies that can damage the baby's RBC that are produced by the mother's incompatible blood are eliminated.[22] Small amounts of the baby's blood are removed and transformed simultaneously with the donor's blood. This process can potentially be carried out in a number of different ways.



Phototherapy:

This is also used to cure jaundice and is referred to as mild treatment. The gentle therapy enables the bilirubin in the infant's skin to be changed into a form that can be eliminated by the infant. Usually, a special light is used to illuminate the baby from above while it is lying on its back. These days, it's even possible to find bendable light pads that wrap around the baby. The eyes are protected from light contact by being stored separately.

Immunoglobulin:

Using intravenous immunoglobulin (IVIG), maternal anti-D antibodies can be neutralised.[23] These can be used to lower RBC breakdown and lower circulating bilirubin levels. IVIG may be used to minimise the time required for phototherapy and reduce the need for blood transfusions.



7. PREVENTION:

Deterrence and Patient Education

A interdisciplinary approach to prognosis and treatment has significantly advanced the diagnosis of this illness. The team of nurses and doctors now has the tools and non-invasive test that, when performed during pregnancy, will activate early popularity and treatment and improve patient care at Level 5.

By doing screening tests and managing the pregnant woman's Rh factor immunoglobulin levels, erythroblastosis fetalis may be prevented. These elements are briefly mentioned below.

Screening:

At the initial prenatal appointment, the blood type of the expectant mother must be checked. Aside from testing for Rh type, several blood types will also be analysed. Additional tests may be necessary in cases of prior pregnancies or blood transfusion history. ABO and Rh types will also be checked in the father's blood.[8] The baby's blood may also need to be tested for ABO and Rh types throughout pregnancy, as well as to see if it reacts with the mother's blood.

Rh Factor Immunoglobulins:

Rho (D) immunoglobulin (RhoGAM) should be given at 28 weeks gestation and within 72 hours of delivery if the expectant mother is susceptible to Rh sensitization.[24] This medication contains high concentrations of anti-Rh antibodies, which render Rh+ foetal RBCs inert. The preparation is administered within 72 hours after delivery or the termination of a pregnancy due to miscarriage, abortion, or ectopic pregnancy since these events increase the likelihood of fetal-maternal transfer and sensitization. The most common dosage is 300 g of RhoGAM administered

intramuscularly (IM). To rule out significant fetal-maternal haemorrhage (FMH), a rosette check may be performed. It must be noted, however, that there is no comparable immunotherapy available for other blood institution incompatibilities.

8. CONCLUSION:

The obstetric nurse is often a part of an interprofessional team that monitors pregnancies. Because erythroblastosis fetalis is avoidable, these specialists strive to ensure that pregnant women no longer get it. Every four weeks or so throughout pregnancy, the antibody titer is checked. Expectant management of the pregnancy is possible as long as it stays under 1:16. Serial amniocentesis should begin as early as 16 to 20 weeks into the pregnancy, but, if the ratio is more than 1:16. Foetal cells may be gathered and checked for the Rh antigen during the first amniocentesis to determine the foetal Rh status. If the test is negative, the pregnancy can be watched carefully. [25]Foetal anaemia is tested for, nevertheless, and foetal centre cerebral artery (MCA) Doppler measures are used if the foetus is Rh-positive. The MCA Doppler measures peak systolic velocity (PSV) because it was proven more than ten years ago that anaemic foetuses may have more blood drifting to the brain. Foetal anaemia demands more intrusive testing and capable therapy in foetuses with higher PSV readings.

REFERENCES:

1. T. Sui, S. Ying, A. M. Korsunsky, and G. Landini, “X-ray study of human dental tissues affected by erythroblastosis fetalis,” *J. Dent. Res.*, vol. 94, no. 7, pp. 1004–1010, 2015, doi: 10.1177/0022034515580987.
2. S. J. Urbaniak, “Alloimmunity to RhD in humans,” *Transfus. Clin. Biol.*, vol. 13, no. 1-2 SPEC. ISS., pp. 19–22, 2006, doi: 10.1016/j.tracli.2006.02.020.
3. R. F. W. Goodwin, D. H. Heard, B. H. G. Hayward, and G. F. Roberts, “Haemolytic disease of the newborn piglet,” *J. Hyg. (Lond).*, vol. 54, no. 2, pp. 153–171, 1956, doi: 10.1017/S0022172400044429.
4. R. M. Fasano, “Hemolytic disease of the fetus and newborn in the molecular era,” *Semin. Fetal Neonatal Med.*, vol. 21, no. 1, pp. 28–34, 2016, doi: 10.1016/j.siny.2015.10.006.
5. M. A. Kucher *et al.*, “Impact of ABO-and Rh-incompatibility in allogeneic hematopoietic stem cell transplantation,” *Cell. Ther. Transplant.*, vol. 7, no. 4, pp. 38–46, 2018, doi: 10.18620/ctt-1866-8836-2018-7-4-38-46.
6. V. Pegoraro *et al.*, “Hemolytic disease of the fetus and newborn due to Rh(D) incompatibility: A preventable disease that still produces significant morbidity and mortality in children,” *PLoS One*, vol. 15, no. 7 July, pp. 1–11, 2020, doi: 10.1371/journal.pone.0235807.
7. T. S. Casina, S. G. Sandler, and S. M. Autenrieth, “Rh immune globulin: An interfering substance in compatibility testing,” *Immunohematology*, vol. 35, no. 2, pp. 51–60, 2020, doi: 10.21307/IMMUNOHEMATOLOGY-2020-013.
8. A. Jain, S. Malhotra, N. Marwaha, P. Kumar, and R. R. Sharma, “Severe ABO hemolytic disease of fetus and newborn requiring blood exchange transfusion,” *Asian J. Transfus. Sci.*, vol. 12, no. 2, pp. 176–179, 2018, doi: 10.4103/ajts.AJTS_106_17.
9. W. J. Kleijer, M. L. T. van der Sterre, V. H. Garritsen, A. Raams, and N. G. J. Jaspers, “Evolution of prenatal detection of neural tube defects in the pregnant population of the city of Barcelona from 1992 to 2006,” *Prenat. Diagn.*, vol. 31, no. 10, pp. 1184–1188, 2011, doi: 10.1002/pd.
10. S. Mandal *et al.*, “Severe hemolytic disease of the fetus and newborn due to anti-E and anti-Jka,” *Immunohematology*, vol. 36, no. 2, pp. 60–63, 2020, doi: 10.21307/IMMUNOHEMATOLOGY-2020-043.
11. J. Salas and J. Northington, “Head Ultrasound in Neonatal Hypoxic-Ischemic Injury and Its Mimickers for Clinicians : A Review of the Patterns of Injury and the Evolution of Findings Over Time,” vol. 21287, pp. 185–197, 2018, doi: 10.1159/000487913.
12. C. Bellini *et al.*, “Etiology of nonimmune hydrops fetalis: A systematic review,” *Am. J. Med. Genet. Part A*, vol. 149, no. 5, pp. 844–851, 2009, doi: 10.1002/ajmg.a.32655.
13. J. E. Hendrickson and M. Delaney, “Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations,” *Transfus. Med. Rev.*, vol. 30, no. 4, pp. 159–164, 2016, doi: 10.1016/j.tmrv.2016.05.008.
14. S. Sainio *et al.*, “Diagnosis and treatment of severe hemolytic disease of the fetus and newborn: A 10-year nationwide retrospective study,” *Acta Obstet. Gynecol. Scand.*, vol. 94, no. 4, pp. 383–390, 2015, doi: 10.1111/aogs.12590.
15. G. A. Denomme and B. J. Fernandes, “Fetal blood group genotyping,” *Transfusion*, vol. 47, no. SUPPL. 1, 2007, doi: 10.1111/j.1537-2995.2007.01313.x.
16. R. Incompatibility, “Erythroblastosis Fetalis,” pp. 5–7, 2020.

17. C. Whybra *et al.*, "Lysosomal storage disorder in non-immunological hydrops fetalis (NIHF) - More common than assumed? Report of four cases with transient NIHF and a review of the literature," *Orphanet J. Rare Dis.*, vol. 7, no. 1, pp. 1–9, 2012, doi: 10.1186/1750-1172-7-86.
18. D. M. Gilby, J. B. Mee, C. O. F. Kamlin, L. H. Kornman, P. G. Davis, and B. J. Manley, "Outcomes following antenatal identification of hydrops fetalis: A single-centre experience from 2001 to 2012," *Arch. Dis. Child. Fetal Neonatal Ed.*, vol. 104, no. 3, 2019, doi: 10.1136/archdischild-2017-313604.
19. M. de Haas, F. F. Thurik, J. M. Koelewijn, and C. E. van der Schoot, "Haemolytic disease of the fetus and newborn," *Vox Sang.*, vol. 109, no. 2, pp. 99–113, 2015, doi: 10.1111/vox.12265.
20. C. E. Van Der Schoot, M. De Haas, and F. B. Clausen, "Genotyping to prevent Rh disease: Has the time come?," *Curr. Opin. Hematol.*, vol. 24, no. 6, pp. 544–550, 2017, doi: 10.1097/MOH.0000000000000379.
21. A. I. Lee and R. M. Kaufman, "Transfusion Medicine and the Pregnant Patient," *Hematol. Oncol. Clin. North Am.*, vol. 25, no. 2, pp. 393–413, 2011, doi: 10.1016/j.hoc.2011.02.002.
22. K. A. Patel, K. A. Raja, J. N. Patel, A. N. Pandya, C. A. Unagar, and S. J. Wadhwani, "Study of Exchange Transfusion by Reconstituted Blood in Hemolytic Disease of Fetus & New Born," *Int. J. Contemp. Med. Res. [IJCMR]*, vol. 6, no. 3, pp. 1–5, 2019, doi: 10.21276/ijcmr.2019.6.3.7.
23. A. A. Nassr *et al.*, "Outcome and Treatment of Antenatally Diagnosed Nonimmune Hydrops Fetalis," *Fetal Diagn. Ther.*, vol. 43, no. 2, pp. 123–128, 2018, doi: 10.1159/000475990.
24. A. L. Randenberg, "Randenberg2010," pp. 281–295, 2010.
25. T. F. Porter, "Management of Alloimmunization During Pregnancy," *Obstet. Gynecol.*, vol. 131, no. 3, pp. 82–90, 2018.